Abstract:Pulmonary hypertension (PH) is a pulmonary vascular disease characterized by a high mortality rate. Pulmonary arterial endothelium cells (PAECs) serve as a primary sensor of various environmental cues, such as shear stress and hypoxia, but PAEC dysfunction may trigger vascular remodeling during the onset of PH. This study was aimed to illustrate the role of SIRT7 in endothelial dysfunction during PH, and explore the potential therapeutic strategy for PH. SIRT7 levels were measured in human and murine experimental PH samples. Bioinformatic analysis, immunoprecipitation, and deacetylation assay was used to identify the association between SIRT7 and Krüpple-like factor 4 (KLF4), a key transcription factor essential for EC homeostasis. Sugen5416+hypoxia (SuHx)-induced PH mouse models and cell cultures were used for the study of the therapeutic effect of SIRT7 for PH. SIRT7 level was significantly reduced in lung tissues and PAECs from PH patients and the SuHx-induced PH mouse model as compared with healthy controls. Pulmonary endothelium-specific depletion of Sirt7 increased right ventricular systolic pressure and exacerbated right ventricular hypertrophy in the SuHx-induced PH model. At the molecular level, we identified KLF4 as a downstream target of SIRT7, which deacetylated KLF4 at K228 and inhibited the ubiquitination-proteasome degradation. Thus, the SIRT7/KLF4 axis maintained PAEC homeostasis by regulating proliferation, migration, and tube formation. PAEC dysfunction was reversed by adeno-associated virus type 1 vector mediated endothelial overexpression of Sirt7 or supplementation with NAD + intermediate nicotinamide riboside which activated Sirt7; both approaches successfully reversed PH phenotypes. The SIRT7/KLF4 axis ensures PAEC homeostasis, and pulmonary endothelium-specific SIRT7 targeting might constitute a PH therapeutic strategy. Pulmonary endothelial cell dysfunction is pivotal in vascular remodeling process during pulmonary hypertension pathogenesis. We identified a SIRT7/KLF4 axis essential for pulmonary endothelial homeostasis, however compromised in pulmonary hypertension patients and animal models. Pulmonary endothelium-specific Sirt7 gene delivery or treatment with NAD + precursor reversed PH phenotypes, providing a new therapeutic strategy for PH. In normal pulmonary artery endothelial cells, SIRT7 deacetylates KLF4 at K228 to maintain its protein stability, promotes endothelial homeostasis and pulmonary vascular function. During pulmonary hypertension pathogenesis, SIRT7 was reduced, resulted in increased acetylation of KLF4, promoting its ubiquitination and degradation in pulmonary endothelial cells. The ultimate endothelial dysfunction contributes to vascular remodeling and accelerated pulmonary hypertension.

Purine synthesis suppression reduces the development and progression of pulmonary hypertension in rodent models

Abstract 11289: Suppression of <i>De Novo</i> Purine Synthesis Reduces Development and Progression of Pulmonary Hypertension in Rodent Models

Loss of M6a Demethylase ALKBH5 Alleviates Hypoxia-Induced Pulmonary Arterial Hypertension Via Inhibiting Cyp1a1 Mrna Decay

Purinergic Dysregulation in Pulmonary Hypertension

NAMPT mediates PDGF-induced pulmonary arterial smooth muscle cell proliferation by TLR4/NF-κB/PLK4 signaling pathway

Upregulation of IRF9 Contributes to Pulmonary Artery Smooth Muscle Cell Proliferation During Pulmonary Arterial Hypertension

--------ATIC promotes pulmonary arterial smooth muscle cell proliferation via the Ras signaling pathway

Abstract 18691: Asporin Attenuates Pulmonary Arterial Smooth Muscle Cell Proliferation and Regulates Pulmonary Hypertension Development

5-Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase/inosine Monophosphate Cyclohydrolase Promotes Pulmonary Arterial Smooth Muscle Cell Proliferation Via the Ras Signaling Pathway.

Sirtuin 1 regulates pulmonary artery smooth muscle cell proliferation: role in pulmonary arterial hypertension

Histone deacetylase inhibitors synergize with sildenafil to suppress purine metabolism and proliferation in pulmonary hypertension

Inhibition of Src activation reverses pulmonary vascular remodeling in experimental pulmonary arterial hypertension via Akt/mTOR/HIF-1<alpha> signaling pathway.

SMYD2-Methylated PPARγ Facilitates Hypoxia-Induced Pulmonary Hypertension by Activating Mitophagy

Established pulmonary hypertension in rats was reversed by a combination of a HIF‐2α antagonist and a p53 agonist

ALDH1A3 Coordinates Metabolism with Gene Regulation in Pulmonary Arterial Hypertension

ATIC-Mediated De Novo Purine Synthesis Protects Endothelial Cells from Disturbed Flow-Induced Injury in Atherosclerosis

Nur77 Downregulation Triggers Pulmonary Artery Smooth Muscle Cell Proliferation and Migration in Mice with Hypoxic Pulmonary Hypertension Via the Axin2-β-catenin Signaling Pathway

Endothelium-specific SIRT7 targeting ameliorates pulmonary hypertension through KLF4 deacetylation

Abstract 17142: Deficiency of Smooth Muscle ADAR1 Exacerbates Vascular Remodeling and Pulmonary Hypertension

Loss of DP1 Aggravates Vascular Remodeling in Pulmonary Arterial Hypertension Via Mtorc1 Signaling

Nur77 Suppresses Pulmonary Artery Smooth Muscle Cell Proliferation Through Inhibition of the STAT3/Pim-1/NFAT Pathway.